3 results
Approved WMOCompleted
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
Approved WMOCompleted
To assess whether there is (cost) effectiveness over a period of 1 year of additive intra-articular injections with a high molecular HA derivate in patients with OA of the knee.
Approved WMOPending
Primary:- To evaluate the safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab- Part 3 Neoadjuvant Cohorts (Cohorts 3c and 3d…